TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24612495

Group type: EXPERIMENTAL
Intervention: Various interventions to improve adherence (e.g., calendar blister packs, patient education programs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simplification of drug regimens (e.g., reducing the number of pills taken per day)
Number of subjects: 0
Study: 23724808

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel plus nadifloxacin 1% cream (combination therapy)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Adapalene 0.1% gel (monotherapy)
Number of subjects: 184
Study: 20010312

Group type: EXPERIMENTAL
Intervention: PCV at 2/3 months of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV at 2/4 months of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV booster responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay cutoff of 0.2 microg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlates of protection for serotype 6B
Number of subjects: 0
Study: 18829518

Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg orally every month
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 19382218

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (100/50 mcg twice daily)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Fluticasone propionate (100 mcg twice daily)
Number of subjects: 248
Study: 15688622

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 day 1 every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topotecan 1.5 mg/m2 daily for 5 days q 21
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PLD in platinum-sensitive subset
Number of subjects: 0
Study: 11583862

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 44
Study: 11301569

Group type: EXPERIMENTAL
Intervention: Ketoprofen 6.25 mg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ketoprofen 12.5 mg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 8162989

Group type: EXPERIMENTAL
Intervention: Terbutaline via Turbuhaler
Number of subjects: 47

Group type: COMPARATOR
Intervention: Salbutamol via P-MDI
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 47
Study: 2463552

Group type: EXPERIMENTAL
Intervention: Rate responsive pacing (minute ventilation sensing rate modulated pacemaker)
Number of subjects: 9
Study: 31227460

Group type: EXPERIMENTAL
Intervention: Endoscope-assisted open reduction and internal fixation (EAORIF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Retromandibular (RM) approach
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 32
Study: 27027878

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar) once daily
Number of subjects: 0
Study: 26554277

Group type: EXPERIMENTAL
Intervention: Tobacco-heating cigarettes
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ultra-low machine yield tobacco-burning cigarettes
Number of subjects: 150
Study: 24726867

Group type: EXPERIMENTAL
Intervention: Caregivers of older adults (≥65 years)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Caregivers of patients with higher LASA QOL scores
Number of subjects: 131
Study: 21134466

Group type: EXPERIMENTAL
Intervention: rHSP60
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rENOLASE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rGAPDH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactivated Ph.d.p. whole bacterial vaccine
Number of subjects: 0
Study: 19552838

Group type: EXPERIMENTAL
Intervention: Serum Chemerin levels in females (109 +/- 28 microg/L)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Serum Chemerin levels in OW/OB group (113 +/- 27 microg/L)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Correlation of serum Chemerin with waist circumference, WHR, fasting serum C peptide, HOMA-IR, TG, ALT, gamma-GT, uric acid
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Fasting serum C peptide and TG as independent variables of Chemerin
Number of subjects: 152
Study: 17094871

Group type: EXPERIMENTAL
Intervention: Oral melatonin 3 mg (M3 group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral melatonin 5 mg (M5 group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No premedication (Placebo group)
Number of subjects: 45
Study: 14743850

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Statin therapy (both groups)
Number of subjects: 161
Study: 11236044

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 28
Study: 9476036

Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 g paracetamol alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan + 1 g paracetamol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan + 10 mg metoclopramide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan + 1 g paracetamol + 10 mg metoclopramide
Number of subjects: 15
Study: 3129954

Group type: EXPERIMENTAL
Intervention: Pethidine 30 mg and doxapram 45 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pethidine 30 mg alone
Number of subjects: 24
Study: 28320218

Group type: EXPERIMENTAL
Intervention: Early cord clamping
Number of subjects: 189

Group type: COMPARATOR
Intervention: Delayed cord clamping
Number of subjects: 189

Group type: COMPARATOR
Intervention: Cord milking
Number of subjects: 189
Study: 27019267

Group type: EXPERIMENTAL
Intervention: Oat bran (40g) with nutrition counseling
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (rice flour) with nutrition counseling
Number of subjects: 132
Study: 24332906

Group type: EXPERIMENTAL
Intervention: eFAST examination performed on-site
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: eFAST examination performed during patient transfer
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: eFAST examination performed in both settings
Number of subjects: 98
Study: 22731641

Group type: EXPERIMENTAL
Intervention: eNOS Glu298Asp polymorphism genotype distribution
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: eNOS allele frequencies
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Serum NO levels correlation with eNOS genotype
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: eNOS genotype distribution correlation with AMI incidence
Number of subjects: 205
Study: 20850831

Group type: EXPERIMENTAL
Intervention: Active treatment group (electrical stimulation)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 56
Study: 18440756

Group type: EXPERIMENTAL
Intervention: AK-EVLA (n = 23)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: EVLA mid-calf to groin (n = 23)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: AK-EVLA + below-knee GSV foam sclerotherapy (n = 22)
Number of subjects: 65
Study: 15811484

Group type: EXPERIMENTAL
Intervention: Exenatide injected subcutaneously into the arm
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Exenatide injected subcutaneously into the thigh
Number of subjects: 28

Group type: COMPARATOR
Intervention: Exenatide injected subcutaneously into the abdomen
Number of subjects: 28
Study: 11952661

Group type: EXPERIMENTAL
Intervention: Topical mupirocin cream applied three times daily
Number of subjects: 159

Group type: COMPARATOR
Intervention: Oral cephalexin, 250 mg four times daily
Number of subjects: 159
Study: 10217339

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg four times daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mexiletine (200 mg oral dose)
Number of subjects: 14
Study: 7899419

Group type: EXPERIMENTAL
Intervention: piperacillin (12 g/d)/tazobactam (1.5 g/d)+amikacin
Number of subjects: 222

Group type: COMPARATOR
Intervention: ceftazidime (3 g/d)+amikacin
Number of subjects: 222
Study: 2650576

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 822265

Group type: EXPERIMENTAL
Intervention: niflumic acid (1000 mg per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: indometazin (100 mg per day)
Number of subjects: 80
Study: 30058942

Group type: EXPERIMENTAL
Intervention: Media literacy intervention (digital argument production or digital story production)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group (assessments only)
Number of subjects: 247
Study: 27564443

Group type: EXPERIMENTAL
Intervention: Manganese and Lipoflavonoid Plus(®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lipoflavonoid Plus(®) only (Control)
Number of subjects: 40
Study: 24426779

Group type: EXPERIMENTAL
Intervention: menatetrenone 45 mg/day
Number of subjects: 236

Group type: COMPARATOR
Intervention: alfacalcidol 0.5 μg/day
Number of subjects: 236
Study: 22341914

Group type: EXPERIMENTAL
Intervention: Sitting position with neck in neutral position
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Neck flexion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Neck extension
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Left lateral decubitus position
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Recumbent positions
Number of subjects: 24
Study: 20350244

Group type: EXPERIMENTAL
Intervention: Early CT (within 24 hours of admission)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Early CT
Number of subjects: 118
Study: 18484550

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 15857725

Group type: EXPERIMENTAL
Intervention: Weekly individual standardized interpersonal cognitive psychotherapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 16 mg buprenorphine every other day
Number of subjects: 90
Study: 14694974

Group type: EXPERIMENTAL
Intervention: Porcine-derived lung surfactant therapy within the first hour of life (Group A, 35 neonates)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No surfactant therapy within the first hour of life (Group B, 40 neonates)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Porcine-derived lung surfactant therapy within the first hour of life (Group A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No surfactant therapy within the first hour of life (Group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Weight of neonates
Number of subjects: 75
Study: 11512056

Group type: EXPERIMENTAL
Intervention: RATG group 1
Number of subjects: 171

Group type: COMPARATOR
Intervention: OKT3 group 1
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: RATG group 2
Number of subjects: 171
Study: 9663834

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 222
Study: 17233169

Group type: EXPERIMENTAL
Intervention: Air-powder polishing for 60 seconds with Concise adhesive
Number of subjects: 96

Group type: COMPARATOR
Intervention: Air-powder polishing for 0, 15, and 30 seconds with Concise adhesive
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Air-powder polishing for 60 seconds with System 1+ adhesive
Number of subjects: 96

Group type: COMPARATOR
Intervention: Air-powder polishing for 0, 15, and 30 seconds with System 1+ adhesive
Number of subjects: 96
Study: 2938515

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide as inhalation powder (40 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ipratropium bromide as aerosol (2 puffs of 20 micrograms)
Number of subjects: 20
Study: 31662373

Group type: EXPERIMENTAL
Intervention: Internet-Based Exercise programme (iBEAT-OA), 20-30 min daily for six weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard community care provided by general practitioners (GPs)
Number of subjects: 134
Study: 30353809

Group type: EXPERIMENTAL
Intervention: 6 mg regular‐release melatonin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patients with Dravet syndrome
Number of subjects: 13
Study: 27314121

Group type: EXPERIMENTAL
Intervention: Machined implants
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Roughened implants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 50
Study: 25081937

Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice packs applied for a minimum of 24 hours)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No cryotherapy (control group)
Number of subjects: 55
Study: 22067793

Group type: EXPERIMENTAL
Intervention: LNG/EE (90 mcg levonorgestrel/20 mcg ethinyl estradiol)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 20420996

Group type: EXPERIMENTAL
Intervention: Kouk-Sun-Do (KSD) exercise, low-intensity, 45-minute sessions, three times a week for 16 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 39
Study: 18798585

Group type: EXPERIMENTAL
Intervention: 0.02% mitomycin-C applied intraoperatively for 3 minutes after pterygium excision
Number of subjects: 65

Group type: COMPARATOR
Intervention: Topical 0.02% mitomycin-C drops twice a day for 2 weeks after pterygium excision
Number of subjects: 65
Study: 15851601

Group type: EXPERIMENTAL
Intervention: Clopidogrel and Aspirin (dual therapy)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Aspirin monotherapy (control)
Number of subjects: 107
Study: 11403068

Group type: EXPERIMENTAL
Intervention: Hirudin (10 micrograms/kg/h, adjusted in 2 micrograms/kg/h steps, targeted ECT 80-100 s)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Heparin (250 IU/h, adjusted in 125 IU/h steps, targeted ACT 180-210 s)
Number of subjects: 17
Study: 9663728

Group type: EXPERIMENTAL
Intervention: famotidine 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: effervescent cimetidine 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 7833101

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 0.5 mg bd
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 1.0 mg bd
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 2.0 mg bd
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride (all doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride
Number of subjects: 80
Study: 3275684

Group type: EXPERIMENTAL
Intervention: 0.3 mg cabergoline
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 0.6 mg cabergoline
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 0.6 mg cabergoline (twice weekly)
Number of subjects: 51

Group type: COMPARATOR
Intervention: bromocriptine
Number of subjects: 51
Study: 1489388

Group type: EXPERIMENTAL
Intervention: Methimazole for 18 months
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Iodine-131 therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Surgical treatment (group 2)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Medical treatment (group 2)
Number of subjects: 168
Study: 860807

Group type: EXPERIMENTAL
Intervention: Oral diazepam and metoclopramide with a drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine and atropine given intramuscularly without a drink
Number of subjects: 0
Study: 31444252

Group type: EXPERIMENTAL
Intervention: calaspargase pegol‐mknl (CALASP), 2,500 U/m2 intravenously, every 3 weeks
Number of subjects: 124

Group type: COMPARATOR
Intervention: calaspargase pegol‐mknl (CALASP)
Number of subjects: 124
Study: 31880803

Group type: EXPERIMENTAL
Intervention: Bundled payments for hip and knee joint replacement operations
Number of subjects: 493977
Study: 28425272

Group type: EXPERIMENTAL
Intervention: Washed red blood cells (WRBC) transfusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonwashed red blood cells (NWRBC) transfusion
Number of subjects: 38
Study: 26375928

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (30 IU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23147384

Group type: EXPERIMENTAL
Intervention: 5 mg day(‐1) GSK1521498
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 2 mg day(‐1) GSK1521498
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 21875814

Group type: EXPERIMENTAL
Intervention: C-arm CT/DSA (test group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: DSA (control group)
Number of subjects: 87
Study: 19242709

Group type: EXPERIMENTAL
Intervention: Diclofenac suppositories
Number of subjects: 200

Group type: COMPARATOR
Intervention: Indomethacin suppositories
Number of subjects: 200
Study: 16758935

Group type: EXPERIMENTAL
Intervention: Xe:O2
Number of subjects: 60

Group type: COMPARATOR
Intervention: N2O:O2+fentanyl
Number of subjects: 60
Study: 15715628

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Desflurane and Sevoflurane
Number of subjects: 160
Study: 11325669

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 9771218

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) for local tumour staging
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) for lymph node staging
Number of subjects: 90

Group type: COMPARATOR
Intervention: Endoscopic ultrasound (EUS) compared to other imaging modalities
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fine needle aspiration biopsy using radial scanning EUS guidance
Number of subjects: 90
Study: 8141609

Group type: EXPERIMENTAL
Intervention: 5‐MOPm plus UVA radiation
Number of subjects: 22

Group type: COMPARATOR
Intervention: 5‐MOP
Number of subjects: 22
Study: 3336100

Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 2% lidocaine viscous solution
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dilute surgical lubricant
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Upper ureteral stones
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mid ureteral stones
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lower ureteral stones
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stones 0.5 cm or less
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stones between 0.6 and 1.0 cm
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stones larger than 1.0 cm
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy or ureteral meatotomy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Repeat extracorporeal shock wave lithotripsy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pelvic stones
Number of subjects: 75
Study: 29282731

Group type: EXPERIMENTAL
Intervention: TAU plus up to 16 sessions of individual formulation‐based CBT for ADHD
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study: 27612178

Group type: EXPERIMENTAL
Intervention: Individualized communication training for oncologists and question prompt lists with individualized communication coaching for patients
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group received no training
Number of subjects: 265
Study: 25633626

Group type: EXPERIMENTAL
Intervention: CyberSenga program
Number of subjects: 366

Group type: COMPARATOR
Intervention: treatment-as-usual control group
Number of subjects: 366
Study: 23615694

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (ARI-OM)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 22142991

Group type: EXPERIMENTAL
Intervention: Diet and Exercise (DE)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Diet Only (DO)
Number of subjects: 206
Study: 19491792

Group type: EXPERIMENTAL
Intervention: Surgical treatment during hospitalization
Number of subjects: 177

Group type: COMPARATOR
Intervention: Conservative therapy following stapedoplasty (1 year or more earlier)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Combined treatment with betahistine dihydrochloride (betaserk) during 2 months and 10-12 sessions of game exercises at a stabilographic complex
Number of subjects: 177
Study: 17110823

Group type: EXPERIMENTAL
Intervention: Nontricyclic antidepressant
Number of subjects: 147
Study: 15601962

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat diets
Number of subjects: 0
Study: 11769814

Group type: EXPERIMENTAL
Intervention: Tryptophan loading
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tryptophan depletion
Number of subjects: 0
Study: 9934406

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg/die per os) + Placebo of fluticasone (2 puff per nostril once daily by aerosol) for 60 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluticasone (100 mg per nostril once daily by aerosol) + Placebo of cetirizine (per os) for 60 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg/die per os) + Fluticasone (100 mg per nostril once daily by aerosol) for 20 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both treatments (Cetirizine and Fluticasone)
Number of subjects: 54
Study: 8148218

Group type: EXPERIMENTAL
Intervention: Colestipol 10 g daily (administered as 5 g twice daily or 10 g once daily)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 3246466

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PL) solution
Number of subjects: 9